Citi Lifts PT on Johnson & Johnson (JNJ) to $274 From $250

Group 1: Investment Potential - Johnson & Johnson (NYSE: JNJ) is highlighted as a highly profitable blue chip stock, with Citi raising its price target from $250 to $274 while maintaining a Buy rating [1] - Citi's research note indicates that despite recent market volatility, the fundamentals of the medical technology sector remain "healthy" [1] - Citi's top picks in the sector include iRhythm and Medtronic, suggesting a competitive landscape [1] Group 2: Product Development and Regulatory Approvals - Johnson & Johnson announced the submission of a Type II variation application to the European Medicines Agency (EMA) for TECVAYLI® to treat adult patients with relapsed/refractory multiple myeloma [2] - The submission is supported by data from the Phase 3 MajesTEC-9 trial, which evaluates teclistamab's safety and efficacy against standard care in 614 patients [3] Group 3: Company Overview - Johnson & Johnson operates through two segments: Innovative Medicine and MedTech, focusing on various therapeutic areas including oncology, infectious diseases, and cardiovascular diseases [4] - The MedTech segment encompasses a wide range of medical devices used in cardiovascular intervention, orthopedics, and surgery [4]